Skip to content
Reipet – Lifestyle
Author:
Liminatus Pharma Inc.
Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline
May 21, 2026
Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody
March 17, 2026